Mithradote Bio raised $1 million in a seed round co-led by Taho Pharma and Vickers Venture Partners to advance the development of a self-administered antidote against drink spiking.

Oct 02, 2024•about 1 year ago

Amount Raised

$1 Million

Round Type

seed

San DiegoBiopharmaPharmaceuticalBiotechnology

Investors

Vickers Venture PartnersTaho Pharma

Description

Mithradote Bio has successfully closed an oversubscribed $1 million seed round to develop M-101, a novel sublingual antidote targeting 'date-rape' drugs. The funding is supported by strategic development partnerships aimed at enhancing their product's formulation and manufacturing capabilities.

Company Information

Company

Mithradote Bio

Location

San Diego, California, United States

About

Mithradote Bio is a biopharmaceutical company with a mission to develop safe and effective products that protect intended targets of drug-facilitated sexual assault. They are focused on creating the first self-administered antidote against drink spiking. The company aims to create innovative solutions for significant global issues. Their flagship product, M-101, is designed to address drug-facilitated sexual assault.

Related People

Funding Insights

Based on industry data

VC-backed spending patterns